Page last updated: 2024-11-05

thiotepa and Cancer of Pelvis

thiotepa has been researched along with Cancer of Pelvis in 1 studies

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Research Excerpts

ExcerptRelevanceReference
"Myeloablative treatment intensification in 25 patients diagnosed when older than 12 months of age with stage IV neuroblastoma included sequential delivery of cisplatin 120 mg/m2 x 1, hyperfractionated radiation (2,100 cGy) to the primary site and adjacent lymph nodes, carmustine (BCNU) 200 mg/m2 x 1, melphalan 60 mg/m2/d x 3 (n = 13) or thiotepa 300 mg/m2/d x 3."3.68Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. ( Cheung, NK; Gulati, SC; Kushner, BH; LaQuaglia, M; Mandell, LR; O'Reilly, RJ, 1991)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kushner, BH1
O'Reilly, RJ1
Mandell, LR1
Gulati, SC1
LaQuaglia, M1
Cheung, NK1

Other Studies

1 other study available for thiotepa and Cancer of Pelvis

ArticleYear
Myeloablative combination chemotherapy without total body irradiation for neuroblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation

1991